Dr. Julie Vose

Professor of Internal Medicine, Division of Oncology & Hematology
University of Nebraska Medical Center

Dr. Julie Vose is an internationally known leading expert in the treatment of patients with lymphoma, and is currently the Neumann M. and Mildred E. Harris Professorial Chair and Chief of the Oncology and Hematology Division in the Department of Internal Medicine at UNMC.

She has served in many national and international review panels and is actively involved in various administrative positions in various local and national organizations and is actively involved in various novel clinical trials.

Dr. Vose is a member of the Nebraska Lymphoma Study Group and the current co-program leader of the Hematologic Malignancy Program at the UNMC Eppley Cancer Center.

Recurrence

CAR T-Cell Therapy: What You Should Know About Side Effects

Treatment

Could New Non-Hodgkin Lymphoma Drugs Mean Less Chemo in the Future?

Recurrence

CAR T-Cell Therapy: How it Works, and Who Can Get It

Prevention & Risk

Non-Hodgkin Lymphoma: It’s More Than Just One Type

What Are the Side Effects of CAR T-Cell Therapy for Non-Hodgkin Lymphoma?

Treatment

CAR T-Cell Therapy for Non-Hodgkin Lymphoma